Central injections of arginine vasopressin prolong extinction of active avoidance

Behavioral and physiological effects of arginine vasopressin (AVP) were examined following intracerebroventricular (ICV) injection in the rat. ICV injections prolonged extinction of active avoidance at doses of 1.0 and 10.0 ng/rat and this effect was blocked by peripheral injection of the vasopressor antagonist of vasopressin [dPtyr(Me)AVP] at a dose of 30 micrograms/kg (SC). However, 1.0 ng of AVP ICV failed to alter systemic blood pressure and also failed to produce taste aversions in a one or two bottle test. Results suggest that central AVP has a central action independent of systemic changes in blood pressure, but that the receptor mediating this action is functionally similar to the AVP V1 (vasopressor) receptor.

[1]  D. Wied.  Long Term Effect of Vasopressin on the Maintenance of a Conditioned Avoidance Response in Rats , 1971, Nature.

[2]  F. Bloom,et al.  Antagonism of effects of vasopressin (AVP) on inhibitory avoidance by a vasopressin antagonist peptide [dPtyr(Me)AVP]. , 1984, Life sciences.

[3]  S. Iversen,et al.  Aversive effects of subcutaneously injected vasopressin in the rat: independence of the ascending dorsal noradrenergic bundle , 1985, Brain Research.

[4]  A. Ettenberg.  Intracerebroventricular application of a vasopressin antagonist peptide prevents the behavioral actions of vasopressin , 1984, Behavioural Brain Research.

[5]  D. Wied,et al.  Oxytocin, vasopressin and memory: opposite effects on consolidation and retrieval processes , 1978, Brain Research.

[6]  B. Gähwiler,et al.  Vasopressin excites hippocampal neurones , 1982, Nature.

[7]  D. B. Duncan.  MULTIPLE RANGE AND MULTIPLE F TESTS , 1955 .

[8]  Q. Pittman,et al.  Central effects of arginine vasopressin on blood pressure in rats. , 1982, Endocrinology.

[9]  D. Wied,et al.  Behavioral effects of intraventricularly administered vasopressin and vasopressin fragments , 1976 .

[10]  D. Wied,et al.  Modification of conditioned behavior of rats by neurohypophyseal hormones and analogues. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Kovacs,et al.  Effect of oxytocin and vasopressin on memory consolidation: sites of action and catecholaminergic correlates after local microinjection into limbic-midbrain structures , 1979, Brain Research.

[12]  D. Lilley.  Molecular biology: Eukaryotic genes—are they under torsional stress? , 1983, Nature.

[13]  G. Kovacs,et al.  A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide. , 1983, Science.

[14]  F. Bloom,et al.  Can aversive properties of (peripherally-injected) vasopressin account for its putative role in memory? , 1983, Behavioural Brain Research.

[15]  M. Moal,et al.  Peripheral injections of vasopressin control behavior by way of interoceptive signals for hypertension , 1985, Behavioural Brain Research.

[16]  J. M. Ree,et al.  Central target for the behavioural effects of vasopressin neuropeptides , 1984, Nature.

[17]  T. W. Greidanus,et al.  Amygdaloid lesions block the effect of neuropeptides (vasopressin, ACTH4–10) on avoidance behavior , 1979, Physiology & Behavior.

[18]  F. Bloom,et al.  Vasopressin pressor antagonist injected centrally reverses behavioral effects of peripheral injection of vasopressin, but only at doses that reverse increase in blood pressure , 1985, Regulatory Peptides.

[19]  M. Manning,et al.  Design of potent antagonists of the vasopressor response to arginine-vasopressin. , 1978, Journal of medicinal chemistry.

[20]  F. Bloom,et al.  Behavioral effects of peripheral administration of arginine vasopressin: a review of our search for a mode of action and a hypothesis , 1984, Psychoneuroendocrinology.

[21]  F. Bloom,et al.  Arginine vasopressin and a vasopressin antagonist peptide: Opposite effects on extinction of active avoidance in rats , 1981, Regulatory Peptides.

[22]  F. Bloom,et al.  Subcutaneous administration of behaviorally effective doses of arginine vasopressin change brain AVP content only in median eminence. , 1986, Neuroendocrinology.

[23]  F. Bloom,et al.  Vasopressin potentiation in the performance of a learned appetitive task: Reversal by a pressor antagonist analog of vasopressin , 1983, Pharmacology Biochemistry and Behavior.

[24]  R. Buijs.  Vasopressin and oxytocin--their role in neurotransmission. , 1983, Pharmacology & therapeutics.

[25]  J. M. Ree,et al.  Vasopressin and memory , 1983 .

[26]  F. Bloom,et al.  Vasopressor receptor antagonist prevents behavioural effects of vasopressin , 1981, Nature.

[27]  A. K. Johnson,et al.  Blood pressure and heart rate responses to microinjection of vasopressin into the nucleus tractus solitarius region of the rat , 1982, Neuropharmacology.

[28]  D. Dorsa,et al.  Localization and characterization of vasopressin-binding sites in the amygdala of the rat brain , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[29]  D. Wied,et al.  Dorsal hippocampus: A site of action of neuropeptides on avoidance behavior? , 1976, Pharmacology Biochemistry and Behavior.

[30]  G. Kovacs,et al.  Facilitation of memory consolidation by vasopressin: Mediation by terminals of the dorsal noradrenergic bundle? , 1979, Brain Research.